Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Apertus Pharmaceuticals
483
•Apertus Pharmaceuticals•October 31, 2025

Apertus Pharmaceuticals – FDA 483, Oct 31, 2025

Record Details

During an inspection conducted from October 27 to October 31, 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Apertus Pharmaceutical LLC, a drug manufacturer located in Ballwin, MO. The inspection revealed several significant observations indicating a failure to adhere to current Good Manufacturing Practices (cGMP) as outlined under the Federal Food, Drug, and Cosmetic Act.

Key observations included a lack of adequate written procedures for production and process controls. Specifically, a 2016 process validation for tablets and capsules identified an assay failure that was never investigated, and the process remains unvalidated. Furthermore, the company's written stability program was deemed inadequate, as it failed to include robust testing for impurities during release and stability testing, and omitted active ingredient assay testing during stability studies for tablets and capsules.

Apertus Pharmaceutical LLC was also cited for accepting supplier certificates of analysis for high-risk components without adequately verifying the supplier's analytical reliability, particularly concerning numerous lots of manufactured tablets and capsules. Lastly, deficiencies were noted within the quality control unit, specifically regarding incomplete and inconsistent data integrity practices. This included infrequent audit trail reviews for critical chromatography-based tests and a lack of documented justification for certain assay integrations.

These observations necessitate Apertus Pharmaceutical LLC to develop and implement comprehensive corrective and preventive actions to ensure the identity, strength, purity, and quality of its drug products, and to bring its operations into full compliance with regulatory requirements.

Company
Apertus Pharmaceuticals
Inspection date
October 31, 2025
Product type
drugs
Office
Kansas City District Office
Person
  • Robert J. Ham (Investigator?)
View Company Profile

ID · ed192c27-89ea-491b-b652-7a9230dba660

Other documents for Apertus Pharmaceuticals
  • 483 - 2020-01-21January 21, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Apertus Pharmaceuticals
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.